Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 322 institutions reported holding it in 13F filings for Q2 2026, worth $7.50B in total; no superinvestor holds it.
Holders of 5% or more of COGT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cogent Biosciences, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%16.6M shares | – | Feb 12, 20251 filing | Feb 12, 2025 | SEC |
| Fairmount Funds Management LLC | 13D/A | 8.60%15.4M shares | −1.30 ppfrom 9.90% | Jul 14, 20254 filings | Mar 31, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.50%11.4M shares | 0.00 ppfrom 6.50% | Jan 21, 20262 filings | Jan 21, 2026 | SEC |
| Flynn James E | 13G | 6.49%9.05M shares | New | Jul 11, 20251 filing | Jul 11, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
25 Schedule 13D and 13G filings on Cogent Biosciences, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 20269:30 PM ET | Fairmount Funds Management LLCand 1 other | 13D/A | 8.60%15.4M shares | −1.30 ppfrom 9.90% | Mar 31, 2026 | SEC |
| Mar 26, 20265:12 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −7.50 ppfrom 7.50%Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20264:42 PM ET | Commodore Capital LPand 3 others | 13G/A | 1.80%2.80M shares | −5.40 ppfrom 7.20%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 202612:43 PM ET | Kynam Capital Management, LPand 2 others | 13G/A | 4.33%6.17M shares | −1.21 ppfrom 5.54%Below 5% | Dec 31, 2025 | SEC |
| Jan 30, 20261:26 PM ET | Vanguard Group Inc | 13G/A | 7.50%11.5M shares | – | Dec 31, 2025 | SEC |
| Jan 22, 20268:02 PM ET | Fairmount Funds Management LLCand 1 other | 13D/A | 9.90%16.3M shares | 0.00 ppfrom 9.90% | Jan 22, 2026 | SEC |
| Jan 21, 20263:47 PM ET | BlackRock, Inc. | 13G/A | 6.50%11.4M shares | 0.00 ppfrom 6.50% | Dec 31, 2025 | SEC |
| Jan 21, 202612:30 PM ET | BlackRock, Inc. | 13G/A | 6.50%11.4M shares | – | Dec 31, 2025 | SEC |
| Nov 17, 20254:36 PM ET | Fairmount Funds Management LLCand 1 other | 13D/A | 9.90%15.9M shares | 0.00 ppfrom 9.90% | Nov 13, 2025 | SEC |
| Nov 14, 20254:57 PM ET | Commodore Capital LPand 3 others | 13G/A | 7.20%10.2M shares | +1.70 ppfrom 5.50% | Sep 30, 2025 | SEC |
| Nov 14, 20254:34 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G/A | 2.30%3.16M shares | −6.80 ppfrom 9.10%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:25 PM ET | TCG Crossover GP I, LLCand 2 others | 13G/A | 4.80%6.80M shares | –Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:16 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 4.00%5.75M shares | −4.70 ppfrom 8.70%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 202512:36 PM ET | Kynam Capital Management, LPand 2 others | 13G/A | 5.54%7.89M shares | – | Sep 30, 2025 | SEC |
| Aug 14, 20256:04 PM ET | Venrock Healthcare Capital Partners II, L.P.and 9 others | 13G/A | 4.20%4.76M shares | −1.60 ppfrom 5.80%Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20255:07 PM ET | Commodore Capital LPand 3 others | 13G | 5.50%6.41M shares | +0.90 ppfrom 4.60% | Jul 7, 2025 | SEC |
| Aug 14, 20255:05 PM ET | Commodore Capital LPand 1 other | 13G/A | 4.60%5.27M shares | –Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20254:31 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G/A | 9.10%10.4M shares | +1.20 ppfrom 7.90% | Jun 30, 2025 | SEC |
| Jul 14, 20254:31 PM ET | Fairmount Funds Management LLCand 1 other | 13D/A | 9.90%14.3M shares | – | Jul 10, 2025 | SEC |
| Jul 11, 20258:19 AM ET | Flynn James Eand 3 others | 13G | 6.49%9.05M shares | New | Jul 7, 2025 | SEC |
| May 15, 20254:39 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G/A | 7.90%8.96M shares | +2.90 ppfrom 5.00% | Mar 31, 2025 | SEC |
| Apr 11, 20256:28 PM ET | Venrock Healthcare Capital Partners II, L.P.and 9 others | 13G/A | 5.80%6.45M shares | – | Sep 30, 2024 | SEC |
| Feb 14, 20254:10 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 8.70%9.99M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20254:35 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G | 5.00%5.56M shares | New | Feb 5, 2025 | SEC |
| Feb 12, 20259:28 AM ET | FMR LLCand 1 other | 13G/A | 15.00%16.6M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Cogent Biosciences, Inc. shares.
No Form 144 notices for Cogent Biosciences, Inc. are on file.